Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies.
Fallah J, Mulkey F, Fiero MH, Gittleman H, Song C, Puthiamadathil J, Amatya A, Agrawal S, Vellanki P, Suzman DL, Singh H, Amiri-Kordestani L, Mishra-Kalyani P, Pazdur R, Kluetz PG. Fallah J, et al. Among authors: suzman dl. J Clin Oncol. 2024 Nov 10;42(32):3783-3787. doi: 10.1200/JCO-24-01200. Epub 2024 Sep 17. J Clin Oncol. 2024. PMID: 39288354
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.
Fallah J, Heiss BL, Joeng HK, Weinstock C, Gao X, Pierce WF, Chukwurah B, Bhatnagar V, Fiero MH, Amiri-Kordestani L, Pazdur R, Kluetz PG, Suzman DL. Fallah J, et al. Among authors: suzman dl. Clin Cancer Res. 2024 Nov 15;30(22):5003-5008. doi: 10.1158/1078-0432.CCR-24-1199. Clin Cancer Res. 2024. PMID: 39248780 Clinical Trial.
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
Brave MH, Maguire WF, Weinstock C, Zhang H, Gao X, Li F, Yu J, Fu W, Zhao H, Pierce WF, Chang E, Dinin J, Fiero MH, Rahman NA, Tang S, Pazdur R, Kluetz PG, Amiri-Kordestani L, Suzman DL. Brave MH, et al. Among authors: suzman dl. Clin Cancer Res. 2024 Nov 1;30(21):4815-4821. doi: 10.1158/1078-0432.CCR-24-1393. Clin Cancer Res. 2024. PMID: 39230571 Clinical Trial.
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.
Fallah J, Xu J, Joeng HK, Weinstock C, Heiss BL, Maguire WF, Gao X, Cheng J, Chang E, Agrawal S, Fiero MH, Pazdur R, Kluetz PG, Amiri-Kordestani L, Suzman DL. Fallah J, et al. Among authors: suzman dl. JCO Precis Oncol. 2024 Aug;8:e2400354. doi: 10.1200/PO.24.00354. JCO Precis Oncol. 2024. PMID: 39208375
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, Bhatnagar V, Svatek RS, Jaigirdar AA, Bross P, Shore N, Kates M, Sachse K, Brewer JR, O'Donnell MA, Steinberg GD, Viviano CJ, Bloomquist E, Ribal MJ, Galsky MD, Oliver R, Black PC, Al-Ahmadie H, Brothers K, Pohar K, Dinney CP, Feng Z, Downs TM, Porten SP, Smith AB, Bangs R, Psutka SP, Agarwal N, Amiri-Kordestani L, Suzman DL, Pazdur R, Kluetz PG, Weinstock C. Chang E, et al. Among authors: suzman dl. Bladder Cancer. 2023 Sep 25;9(3):271-286. doi: 10.3233/BLC-230056. eCollection 2023. Bladder Cancer. 2023. PMID: 38993184 Free PMC article.
42 results